SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Indivior Pharmaceuticals, Inc.

(Name of Issuer)

Common stock, $0.001 par value per share

(Title of Class of Securities)

(CUSIP Number)

Martin Boskovich
333 South Grand Avenue, 28th Floor
Los Angeles, CA, 90071
(213) 830-6759

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Oaktree Value Opportunities Fund, L.P.
2	Check the appropriate box if a member of a Group (See Instructions)

☐ (a)
☐ (b)

3 SEC use only

4 Source of funds (See Instructions)

WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

☐

6 Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:		
	7	Sole Voting Power 0.00
	8	Shared Voting Power 385,037.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 385,037.00

11 Aggregate amount beneficially owned by each reporting person

385,037.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

☐

13 Percent of class represented by amount in Row (11)

0.32 %

14 Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported securities represent 385,037 shares of common stock ("Common Stock") issuable upon conversion of Notes (as defined below). The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on August 3, 2026 (the "Form 10-Q"), and as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

CUSIP No.

1 Name of reporting person

Oaktree London Liquid Value Opportunities Fund (VOF), L.P.

2 Check the appropriate box if a member of a Group (See Instructions)

☐ (a)
☐ (b)

3 SEC use only

4 Source of funds (See Instructions)

WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 180,169.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 180,169.00
11	Aggregate amount beneficially owned by each reporting person 180,169.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 0.15 %	
14	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: The reported securities represent 180,169 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Oaktree Phoenix Investment Fund, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each	7	Sole Voting Power 0.00
	8	Shared Voting Power

Reporting Person With:		51,271.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 51,271.00

11	Aggregate amount beneficially owned by each reporting person 51,271.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 0.04 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The reported securities represent 51,271 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Oaktree Capital Management, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☑
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 292,576.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 292,576.00

11	Aggregate amount beneficially owned by each reporting person

	292,576.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13	Percent of class represented by amount in Row (11) 0.25 %
14	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The reported securities represent 292,576 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Oaktree Fund GP I, L.P.		
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)		
3	SEC use only		
4	Source of funds (See Instructions) WC		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐		
6	Citizenship or place of organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00	
	8	Shared Voting Power 616,477.00	
	9	Sole Dispositive Power 0.00	
	10	Shared Dispositive Power 616,477.00	
11	Aggregate amount beneficially owned by each reporting person 616,477.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐		
13	Percent of class represented by amount in Row (11) 0.52 %		
14	Type of Reporting Person (See Instructions)		

PN

Comment for Type of Reporting Person: The reported securities represent 616,477 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Oaktree Capital Holdings, LLC	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 909,053.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 909,053.00
11	Aggregate amount beneficially owned by each reporting person 909,053.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 0.76 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: The reported securities represent 909,053 shares of Common Stock issuable upon conversion of Notes. The reported percentage is calculated based on 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed in the Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common stock, $0.001 par value per share

(b) Name of Issuer:

Indivior Pharmaceuticals, Inc.

(c) Address of Issuer's Principal Executive Offices:

10710 Midlothian Turnpike, Suite 125, North Chesterfield, VIRGINIA , 23235.

Item 1 Comment: This Amendment No. 6 (this "Amendment No. 6") amends and supplements the Schedule 13D, originally filed on October 2, 2024, as amended by Amendment No. 1 filed on November 7, 2024, as amended by Amendment No. 2 filed on December 18, 2024, as amended by Amendment No. 3 filed on March 4, 2025, as amended by Amendment No. 4 filed on November 13, 2025, and as amended by Amendment No. 5 filed on December 30, 2025. Except as set forth herein, the Schedule 13D remains in full force and effect. Each capitalized term used but not defined herein has the meaning ascribed to such term in the Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended and supplemented to insert the following at the end thereof: On various dates since the filing of Amendment No. 5, the Reporting Persons and certain of their affiliated funds and accounts engaged in open market purchases and sales of the Issuer's 0.625% Convertible Senior Notes due 2031 (the "Notes"), which are convertible into shares of Common Stock at an approximate conversion rate of $41.66 per share. The purchases of the Notes were pursuant to open market transactions, funded with working capital. As of the filing of this Statement, the Reporting Persons beneficially own an aggregate principal amount of $37.872 million of Notes convertible into 909,053 shares of Common Stock.

Item 5. Interest in Securities of the Issuer

(a) Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended and restated as follows and as set forth in subsection (b), (c) and (e) hereto: The information set forth in rows (11) and (13) of each cover page of this Amendment No. 6 is incorporated by reference into this Item 5(a). The Reporting Persons beneficially own an aggregate of 909,053 shares of Common Stock issuable upon conversion of $37.872 million of Notes, representing 0.76% of the Common Stock outstanding as of the date hereof. All such ownership percentages of the securities reported herein are calculated assuming 118,013,649 shares of Common Stock outstanding as of July 28, 2026, as disclosed by the Issuer in its Form 10-Q, as increased by 909,053 shares of Common Stock issuable upon conversion of Notes beneficially owned by the Reporting Persons. In this regard, OVO Fund is the direct holder of 385,037 shares of Common Stock issuable upon conversion of Notes. VOF Fund is the direct holder of 180,169 shares of Common Stock issuable upon conversion of Notes. OPI Fund is the direct holder of 51,271 shares of Common Stock issuable upon conversion of Notes. OC Management is the investment manager to Boston Patriot Arlington St LLC, an SMA account which directly holds 103,622 shares of Common Stock issuable upon conversion of Notes. OC Management is also the investment manager of, and has included in its beneficial ownership securities held by, certain affiliated funds and accounts of the Reporting Persons that collectively hold 188,954 shares of Common Stock issuable upon conversion of Notes. Oaktree GP I is the indirect general partner of OVO Fund, VOF, and OPI Fund, and as such may be deemed to beneficially own an aggregate of 616,477 shares of Common Stock issuable upon conversion of Notes. OC Holdings is the indirect general partner of OVO Fund, VOF, OPI Fund, and Oaktree GP I, and is the sole managing member of the general partner of OC Management, and as such may be deemed to beneficially own an aggregate of 909,053 shares of Common Stock issuable upon conversion of Notes. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, and the filing of this Statement shall not be construed as an admission of such beneficial ownership for the purposes of Section 13(d) or 13(g) of the Exchange Act or for any other purpose.

(b) The information set forth in rows (7) through (10) of each cover page of this Amendment No. 6 and the information set forth in Item 5(a) hereof is incorporated by reference into this Item 5(b).

(c) Within the last 60 days of the filing of this Amendment No. 6, the Reporting Persons have disposed of shares of Common Stock in open market transactions (collectively, the "Common Stock Transactions") as follows: Date Purchase/Sale Amount of Shares Price 26-Jun Sale 231,398 42.1308 26-Jun Sale 118,602 41.7051 16-Jul Sale 14,900 40.614 16-Jul Sale 25,100 40.6395 5-Aug Sale 432,613 38.8552 6-Aug Sale 428,711 39.2151 10-Aug Sale 235,364 38.6389 10-Aug Sale 143,935 38.5563 11-Aug Sale 303,621 38.7858 12-Aug Sale 4,542,968 37.75 Within the last 60 days of the filing of this Amendment No. 6, the Reporting Persons and certain of their affiliated funds and accounts have acquired and disposed of Notes in open market transactions as follows (collectively, the "Notes Transactions" and, together with the Common Stock Transactions, the "Transactions"): Date Purchase/Sale Principal Amount Price 23-Jun Sale $91,000 118.104 25-Jun Sale $70,000 120.327 9-Jul Purchase $500,000 121.285 4-Aug Sale $1,750,000 111.904 5-Aug Sale $2,000,000 116.201 6-Aug Sale $2,000,000 116.278 12-Aug Sale $111,000 114.168

(e) As a result of the Transactions on or prior to August 10, 2026, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on such date. Additional sales on August 11, 2026 resulted in a material shift in ownership requiring the filing of this Amendment No. 6, which serves as an exit filing by the Reporting Persons.

Item 7. Material to be Filed as Exhibits.

Exhibit 24.1 Joint Filing Agreement, dated as of August 13, 2026, by and among the Reporting Persons

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Oaktree Value Opportunities Fund, L.P.

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

Oaktree London Liquid Value Opportunities Fund (VOF), L.P.

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

Oaktree Phoenix Investment Fund, L.P.

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

Oaktree Capital Management, L.P.

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

Oaktree Fund GP I, L.P.

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

Oaktree Capital Holdings, LLC

Signature: /s/ Henry Orren
Name/Title: Henry Orren / Managing Director
Date: 08/13/2026

EXHIBIT 24.1

JOINT FILING AGREEMENT

In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and any subsequent amendments thereto, and have duty executed this joint filing agreement as of the date set forth below.

August 13, 2026

OAKTREE VALUE OPPORTUNITIES FUND, L.P.

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director

OAKTREE LONDON LIQUID VALUE OPPORTUNITIES FUND (VOF), L.P.

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director

OAKTREE PHOENIX INVESTMENT FUND, L.P.

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director

OAKTREE CAPITAL MANAGEMENT, L.P.

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director

OAKTREE FUND GP I, L.P.

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director

OAKTREE CAPITAL HOLDINGS, LLC

By:	/s/ Henry Orren
Name:	Henry Orren
Title:	Managing Director